Value
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.3 |
| P/S | 9.6 |
| EV/EBITDA | 6.5 |
| Fwd P/E | 9.0 |
| PEG | 6.3 |
| Analyst target | 7.5 |
- ▸Forward P/E: 11.7x
- ▸PEG: 1.17
- ▸Attractively valued
HCA · Why this verdict
Why HCA Healthcare (HCA) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A medical care facilities operator with four consecutive earnings beats, best-in-class peer margins, and an attractive forward valuation of 11.8x offers roughly 16% upside to the analyst consensus target in a technical recovery setup — with the primary risk being that soft underlying growth limits re-rating potential beyond the current target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Although the stock remains below its 200-day moving average following a death cross, the long-term average slope is still marginally positive and on-balance volume is rising — suggesting the current weakness is a pullback within a longer uptrend rather than a confirmed breakdown. Momentum breakdown | RSI recovers above 55 and on-balance volume sustains its upward trend for 4 consecutive weeks, confirming the recovery interpretation. | →Stable |
| CounterThe death cross has not yet reversed, and a recovery reading is still speculative; if the broader environment weakens, the stock could slide further below its moving average and confirm a genuine trend change to the downside. | ||
The company ranks best-in-class for margins within its medical care sector peer group, demonstrating an operational advantage that supports earnings durability even during periods of soft revenue growth. Peer-rank breakdown | Peer-relative quality rank stays above 7 out of 10 for 2 consecutive annual periods, confirming the margin leadership is structural rather than cyclical. | →Stable |
| CounterThe quality assessment flags the absence of a competitive moat, meaning the peer-leading margins may be vulnerable to labor cost pressures or reimbursement rate changes rather than protected by a durable structural advantage. | ||
The company has delivered above-estimate earnings in all four of the past four quarters, with an average positive surprise of roughly 9% — including a narrow 0.3% beat in the most recent period — a streak that reflects consistent under-promising and over-delivering and has supported the stock's relative valuation. Catalyst breakdown | Beat streak extends to 6 consecutive quarters with average quarterly surprise remaining above 5%. | →Stable |
| CounterThe most recent beat was just 0.3% above consensus — a margin so thin that any prior guidance conservatism may have been largely consumed; the next miss could arrive without warning and break the streak abruptly. | ||
At a forward P/E of 11.8x and a PEG of 1.18, the stock screens attractively valued for a medical care operator of this scale, with roughly 16% headroom to the analyst consensus price target of $453. Valuation breakdown | Stock closes above $453 within 12 months as the valuation re-rates toward analyst consensus. | →Stable |
| CounterThe bear case cites weak underlying growth, which could prevent the multiple from expanding; without a revenue reacceleration, the stock may remain range-bound at current valuation levels rather than converging to the analyst target. | ||
Although the stock remains below its 200-day moving average following a death cross, the long-term average slope is still marginally positive and on-balance volume is rising — suggesting the current weakness is a pullback within a longer uptrend rather than a confirmed breakdown.
→StableMomentum breakdown
- Expectation
- RSI recovers above 55 and on-balance volume sustains its upward trend for 4 consecutive weeks, confirming the recovery interpretation.
CounterThe death cross has not yet reversed, and a recovery reading is still speculative; if the broader environment weakens, the stock could slide further below its moving average and confirm a genuine trend change to the downside.
The company ranks best-in-class for margins within its medical care sector peer group, demonstrating an operational advantage that supports earnings durability even during periods of soft revenue growth.
→StablePeer-rank breakdown
- Expectation
- Peer-relative quality rank stays above 7 out of 10 for 2 consecutive annual periods, confirming the margin leadership is structural rather than cyclical.
CounterThe quality assessment flags the absence of a competitive moat, meaning the peer-leading margins may be vulnerable to labor cost pressures or reimbursement rate changes rather than protected by a durable structural advantage.
The company has delivered above-estimate earnings in all four of the past four quarters, with an average positive surprise of roughly 9% — including a narrow 0.3% beat in the most recent period — a streak that reflects consistent under-promising and over-delivering and has supported the stock's relative valuation.
→StableCatalyst breakdown
- Expectation
- Beat streak extends to 6 consecutive quarters with average quarterly surprise remaining above 5%.
CounterThe most recent beat was just 0.3% above consensus — a margin so thin that any prior guidance conservatism may have been largely consumed; the next miss could arrive without warning and break the streak abruptly.
At a forward P/E of 11.8x and a PEG of 1.18, the stock screens attractively valued for a medical care operator of this scale, with roughly 16% headroom to the analyst consensus price target of $453.
→StableValuation breakdown
- Expectation
- Stock closes above $453 within 12 months as the valuation re-rates toward analyst consensus.
CounterThe bear case cites weak underlying growth, which could prevent the multiple from expanding; without a revenue reacceleration, the stock may remain range-bound at current valuation levels rather than converging to the analyst target.
Per-dimension breakdown
Quality
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 8.2 |
| Gross margin | 4.3 |
| Op margin | 6.0 |
| Net margin | 4.4 |
| Current ratio | 3.3 |
| FCF quality | 6.2 |
| Moat | 5.1 |
| Piotroski F | 8.9 |
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 8/9
Growth
3.9/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.6 |
| EPS growth | 4.2 |
Momentum
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+0.1%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.0 |
| Analyst rating | 7.5 |
| Price target | 8.5 |
- ▸LLM news sentiment: +0.60 (n=1)
- ▸Analyst upside: 29%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
5.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.9 |
| quality rank | 8.1 |
| growth rank | 3.3 |
- ▸Best-in-class margins
Technical
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.8 |
| support resistance | 2.9 |
| 52w position | 3.9 |
Risk (lower is worse)
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.2 |
| days to cover | 7.1 |
| volatility | 5.2 |
| put call | 7.8 |
| implied vol | 7.0 |
| max pain risk | 7.0 |
| beta | 6.5 |
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 7.1 |
| dividend safety | 6.0 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 80.0%
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (8)
- MOMENTUM:5.8>=5.5
- ASYMMETRY:2.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.60
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
2.08
Upside
+16.4%
Downside
7.9%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 63
EdgeCATALYST — Earnings in 29d with 4/4 beat streak
SuitabilityMODERATE — Balanced profile
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.8>=5.5. Top dim: Sentiment at 8.0; weakest: Technical at 3.2. No conviction either direction.
The strongest dimensions are Sentiment at 8.0, Value at 7.8, and Risk (lower is worse) at 7.0; the weakest are Technical at 3.2, Growth at 3.9, and Insider at 5.0. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 2.08 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has delivered above-estimate earnings in all four of the past four quarters, with an average positive surprise of roughly 9% — including a narrow 0.3% beat in the most recent period — a streak that reflects consistent under-promising and over-delivering and has supported the stock's relative valuation.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, ending the perfect beat streak.
- P2At a forward P/E of 11.8x and a PEG of 1.18, the stock screens attractively valued for a medical care operator of this scale, with roughly 16% headroom to the analyst consensus price target of $453.
Trip ifStock closes above $453 for 4 consecutive weeks without a subsequent upward revision in analyst price target, indicating the valuation discount has fully closed.
- P3Although the stock remains below its 200-day moving average following a death cross, the long-term average slope is still marginally positive and on-balance volume is rising — suggesting the current weakness is a pullback within a longer uptrend rather than a confirmed breakdown.
Trip ifRSI falls below 35 and on-balance volume turns negative for 2 consecutive weeks, confirming a failed recovery attempt.
- P4The company ranks best-in-class for margins within its medical care sector peer group, demonstrating an operational advantage that supports earnings durability even during periods of soft revenue growth.
Trip ifPeer-relative quality rank falls below 5 out of 10 for 2 consecutive reporting periods, indicating loss of best-in-class margin standing.